Developing a new class of orally available therapeutics for high impact targets
Wayfinder is neutralizing the toxic effects of key disease genes by turning them off at the source, their mRNA.
Most diseases are driven by disregulated proteins. Traditional therapies try to block these proteins directly, but many key targets remain untreatable despite decades of research. At Wayfinder, we take a different approach—stopping harmful proteins before they’re even made. We develop small molecules that bind to the mRNAs encoding these proteins, preventing their production in the first place.
We are building a pipeline of small molecule assets for targets inaccessible by traditional drug development approaches.
Our platform discovers selective small molecules that
functionally modulate specific RNA targets.
Centered around Wayfinder’s unique RNA-based sensors and data generation engine, our proprietary technology combines experimental and AI/ML screening to discover potent, selective and biologically active RNA-targeting small molecules. The Wayfinder platform powers a scalable approach for uniquely quantitative insights not only on the binding of small molecules to RNA, but also on their selectivity and function.
Our Pipeline
| Target | Indication | Target ID | Discovery | Hit-To-Lead | Program |
|---|---|---|---|---|---|
| c-MYC | Oncology |  |
|||
| Multiple targets | Undisclosed | |
|||
| Undisclosed | Neurodegeneration |
collaboration
|
Our technology is broadly applicable to RNA targets across disease areas and indications.
Partnering areas of interest include oncology, neurodegeneration, immunology, rare disease.